Darapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model

Darapladib inhibits atherosclerosis development in type 2 diabetes mellitus Sprague-Dawley rat model

Objective. Increase in the low-density lipoprotein (LDL) level in diabetes mellitus and atherosclerosis is related to lipoprotein associated phospholipase A2 (Lp-PLA2). Lp-PLA2 is an enzyme that produces lysophosphatidylcholine (LysoPC) and oxidized nonesterified fatty acids (oxNEFA). LysoPC regulat...

Full description

Bibliographic Details
Main Authors: Wihastuti Titin Andri, Heriansyah Teuku, Hanifa Hanifa, Andarini Sri, Sholichah Zuhrotus, Sulfia Yuni Hendrati, Adam Aditya Angela, Refialdinata Jeki, Lutfiana Nurul Cholifah
Format: Article
Language:English
Published: Sciendo 2018-04-01
Series:Endocrine Regulations
Subjects:
darapladib
atherosclerosis
type 2 diabetes mellitus rat model
Online Access:https://doi.org/10.2478/enr-2018-0008
Description
Summary:Objective. Increase in the low-density lipoprotein (LDL) level in diabetes mellitus and atherosclerosis is related to lipoprotein associated phospholipase A2 (Lp-PLA2). Lp-PLA2 is an enzyme that produces lysophosphatidylcholine (LysoPC) and oxidized nonesterified fatty acids (oxNEFA). LysoPC regulates inflammation mediators, including intra-cellular adhesion molecule-1 (ICAM-1). Darapladib is known as a Lp-PLA2 specific inhibitor. The aim of this study was to reveal the effect of darapladib on the foam cell number, inducible nitric oxide synthase (iNOS), and ICAM-1 expression in aorta at early stages of the atherosclerosis in type 2 diabetes mellitus Sprague-Dawley rat model.
ISSN:1336-0329

Similar Items